Hutchison Chi-Med Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (30)

Latest Posts

About This Stock More About This Stock
Week In Review: BeiGene Forges $1.3 Billion Bi-Specific Antibody Deal With Zymeworks
Article By: ChinaBio® Today
Saturday, December 1, 2018 4:44 PM EST
BeiGene of Beijing announced cancer drug deals worth up to $1.3 billion with Vancouver's Zymeworks. BeiGene will acquire Asian rights to two bispecific antibodies from Zymeworks and will have rights to three to-be-discovered bispecific candidates.
In this article: LLY, HCM, BGNE, MGNX, ZLAB, TCON, ZYME, BHVN
Read
Week In Review: Innovent's Hong Kong IPO: Raising $422 Million At $2 Billion Valuation
Article By: ChinaBio® Today
Saturday, October 20, 2018 4:16 PM EST
Innovent Biologics of Suzhou plans to raise $422 million in its Hong Kong IPO at a $2 billion valuation, according to multiple media reports. The company, formed in 2011, struck a major $1 billion collaboration with Lilly in 2015.
In this article: LLY, APDN, CGIX, HCM
Read
Week In Review: Jiangsu Hansoh To Raise Up To $3 Billion In Hong Kong IPO
Article By: ChinaBio® Today
Saturday, September 8, 2018 4:22 PM EST
Hansoh, a China pharma based in Lianyungang, Jiangsu province, has applied to stage an IPO on the Hong Kong exchange. Unlike most companies seeking Hong Kong IPOs, Hansoh is both profitable and established.
In this article: GSK, LLY, BGNE, ZLAB, ROG, HCM, MRK
Read
Week In Review: Alibaba Bids $1.4 Billion For IKang, A Chain Of China Healthcare Clinics
Article By: ChinaBio® Today
Saturday, March 17, 2018 5:28 PM EST
Alibaba's investment arm and Yunfeng Capital offered $1.4 billion to acquire iKang Healthcare, a chain of private China healthcare clinics. Alibaba will likely incorporate iKang's 110 clinics into its network of online/offline healthcare offerings.
In this article: BABA, RWLK, HCM, KANG
Read
Week In Review: China Pharma Deals Top $1.5 Billion For Week
Article By: ChinaBio® Today
Saturday, March 10, 2018 6:04 PM EST
Tianjin Tasly Pharma (SHA: 600535) is in talks to IPO its biopharma division in Hong Kong later this year with the goal of raising $1 billion. If it happens, the IPO will probably be Hong Kong's largest biopharma IPO this year.
In this article: HCM
Read

PARTNER HEADLINES

Latest Tweets for $HCM

No tweets yet!